Answers are grounded in this paper and cite their sources.
Retrospective analysis evaluates nivolumab outcomes in metastatic lung cancer based on COVID-19 vaccine type, indicating no significant differences in efficacy or safety.
BACKGROUND/AIM: The effect of COVID-19 vaccine type on the outcomes of therapy immune checkpoint inhibitors remains unclear, and concerns persist regarding whether mRNA-based vaccines may negatively impact treatment efficacy or increase immune-related toxicity. This study aimed to evaluate the association between COVID-19 vaccination type and the efficacy and safety of nivolumab in patients with metastatic non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We retrospectively analyzed 138 patients with driver-negative metastatic NSCLC treated with second-line nivolumab. Patients were classified as receiving virion-based (Sinovac) only, mRNA-based only, or both types of vaccines. Treatment response, progression-free survival, objective response rate, clinical benefit rate clinical benefit rate and immune-related adverse events were compared. The incidence of any-grade and grade 3-4 immune-related adverse events was comparable across groups, although grade 1-2 immune-related adverse events were more frequent among patients who had received at least one dose of Sinovac. CONCLUSION: In patients with metastatic NSCLC receiving second-line nivolumab, the efficacy and safety profile of nivolumab did not differ according to the type of COVID-19 vaccine patients had received prior to therapy.
No takes yet. Share an insight, caveat, or question.
Karabuğa et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: